SequelSEC

CURIS INC CRIS

Biological Products, (No Diagnostic Substances) · CIK 0001108205 · Fiscal year ends 1231

Revenue
$4.31M
Fiscal year ended 2026-06-30
Operating income
-$8.76M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

CURIS INC (CRIS) reported revenue of $4.31M and net income of -$21.15M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from CURIS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

CURIS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$4.31M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$8.76M
Net income-$21.15M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$14.83M
Selling & marketingUnavailable

Balance

CURIS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$5.07M
Total assets$18.97M
Current assets$6.72M
Total liabilities$14.28M
Current liabilities$13.68M
Total equity incl. NCI$4.70M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
Goodwill$8.98M
Long-term debtUnavailable
Accounts payable$5.39M

Cash flow

CURIS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$30.59M
Capital expendituresUnavailable
Investing cash flow$2.50M
Financing cash flow$23.02M
Net change in cash-$5.06M
Stock-based compensation$2.86M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$84.00K

Derived

CURIS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-203.2%
FCF marginUnavailable
SBC / revenue66.4%
Current ratio0.49x
Revenue YoY growth-62.2%
Net margin-490.3%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CRIS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-24View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.